FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3043497346> ?p ?o ?g. }

• W3043497346 endingPage "665" @default.
• W3043497346 startingPage "665.2" @default.
• W3043497346 abstract "Background: It is well known that Lupus anticoagulant (LAC) positivity is more strongly associated with both arterial and venous thrombosis than either anticardiolipin (aCL) or anti-β2glycoprotein (aB2GPI) antibodies (1). An unanswered question is the contribution of which combinations of positive aPLs to thrombosis risk. Objectives: We aimed to evaluate which aPL combinations increase the risk of future thrombosis in patients with Systemic Lupus Erythematosus (SLE). Methods: This prospective analysis included SLE patients who had been tested for all 3 aPLs in Hopkins Lupus Cohort. We constructed a dataset with one record per month of follow up for each patient. Rates of thrombosis for each aPL or each combination of aPL were calculated as the number of thromboses divided by the number of person months at risk and the results are converted to rates per 1000 person-years. Results: There were 805 patients with a complete profile of 7 aPLs with a total of 73417 person months of follow up. LAC was the most predictive of any [3.47 (1.96, 6.14) p<0.0001], venous [4.3 (1.99, 9.25) p=0.0002], and arterial [3.37 (1.51, 7.53) p= 0.0029] thrombosis. In individual models, aB2GPI positivity was a significant risk factor for any [1.90 (1.16, 3.13) p=0.0113] and venous [2.3(1.23, 4.61) p=0.0103] thrombosis. When we looked at patients who were LAC positive, and asked if having another positive aPL increase the risk ratio for any/venous/arterial thrombosis, we found that having aB2GPI IgA appeared to add significant risk to any [1.68 (1.01, 2.79) p=0.044], and venous [2.01 (1.02, 3.97) p=0.043] thrombosis among those with or without LAC (Table 1). Table 1. Additive effect of other aPLs adjusting for LAC ANY thrombosis VENOUS thrombosis ARTERIAL thrombosis age adjusted RR 95%(CI ) P - value age adjusted RR 95%(CI ) p-value age adjusted RR 95%(CI ) p-value Model 1: LAC + aCL-G LAC (+) vs (-) 3.78 (2.08, 6.85) <.0001 5.03 (2.25, 11.24) <.0001 3.32 (1.43, 7.73) 0.0053 aCL-G (+) vs (-) 0.64 (0.22, 1.83) 0.4045 0.48 (0.11, 2.14) 0.3351 1.09 (0.31, 3.77) 0.8962 Model 2: LAC + aCL-M LAC (+) vs (-) 3.82 (2.13, 6.87) <0.0001 4.57 (2.07, 10.08) 0.0002 3.69 (1.61, 8.46) 0.0021 aCL-M (+) vs (-) 0.51 (0.16, 1.65) 0.2576 0.68 (0.16, 2.93) 0.6019 0.61 (0.14, 2.64) 0.5075 Model 3: LAC+ aCL-A LAC (+) vs (-) 3.34 (1.88, 5.96) 0.0001 4.14 (1.9, 9) 0.0003 3.29 (1.47, 7.38) 0.0038 aCL-A (+) vs (-) 2.33 (0.56, 9.70) 0.2459 2.44 (0.32, 18.4) 0.3858 2.2 (0.29, 16.49) 0.4415 Model 4: LAC+ aB2GPI-G LAC (+) vs (-) 3.52 (1.94, 6.39) 0.0001 4.21 (1.85, 9.57) 0.0006 3.4 (1.48, 7.79) 0.0038 aB2GPI-G (+) vs (-) 0.91 (0.32, 2.61) 0.8655 1.1 (0.31, 3.88) 0.8849 0.96 (0.22, 4.18) 0.957 Model 5: LAC+ aB2GPI-M LAC (+) vs (-) 3.53 (1.97, 6.31) 0.0021 4.17 (1.9, 9.14) 0.0004 3.58 (1.58, 8.1) 0.0023 aB2GPI-M (+) vs (-) 0.91 (0.49, 1.73) 0.7782 1.17 (0.51, 2.68) 0.7101 0.74 (0.29, 1.9) 0.5285 Model 6: LAC+ aB2GPI-A LAC (+) vs (-) 3.16 (1.77, 5.65) 0.0001 3.68 (1.68, 8.08) 0.0012 3.19 (1.41, 7.2) 0.0052 aB2GPI-A (+) vs (-) 1.68 (1.01, 2.79) 0.0441 2.01 (1.02, 3.97) 0.0434 1.4 (0.67, 2.91) 0.3738 Conclusion: Our study shows that LAC is still the best predictor of risk of any, arterial and venous thrombosis in SLE. Moreover, aB2GPI IgA positivity appeared to add also a significant risk to any and venous thrombosis. Therefore, the clinical significance of IgA anti-β2GPI deserves further investigation in SLE patients. References: [1]Galli M, Luciani D, Bertolini G, Barbui T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood. 2003;101(5):1827-32. Acknowledgments: The Hopkins Lupus Cohort was funded by NIH grant number RO1 AR069572. Disclosure of Interests: Selcan Demir: None declared, Jessica Li: None declared, Laurence Magder: None declared, Michelle A Petri Grant/research support from: GSK, Eli Lilly and Company, Consultant of: Eli Lilly and Company" @default.
• W3043497346 created "2020-07-23" @default.
• W3043497346 creator A5013422165 @default.
• W3043497346 creator A5067204386 @default.
• W3043497346 creator A5079843231 @default.
• W3043497346 creator A5082713013 @default.
• W3043497346 date "2020-06-01" @default.
• W3043497346 modified "2023-09-27" @default.
• W3043497346 title "FRI0163 ANTIPHOSPHOLIPID PATTERNS PREDICT THE RISK OF THROMBOSIS IN SYSTEMIC LUPUS ERYTHEMATOSUS" @default.
• W3043497346 doi "https://doi.org/10.1136/annrheumdis-2020-eular.1888" @default.
• W3043497346 hasPublicationYear "2020" @default.
• W3043497346 type Work @default.
• W3043497346 sameAs 3043497346 @default.
• W3043497346 citedByCount "0" @default.
• W3043497346 crossrefType "journal-article" @default.
• W3043497346 hasAuthorship W3043497346A5013422165 @default.
• W3043497346 hasAuthorship W3043497346A5067204386 @default.
• W3043497346 hasAuthorship W3043497346A5079843231 @default.
• W3043497346 hasAuthorship W3043497346A5082713013 @default.
• W3043497346 hasBestOaLocation W30434973461 @default.
• W3043497346 hasConcept C126322002 @default.
• W3043497346 hasConcept C141071460 @default.
• W3043497346 hasConcept C188816634 @default.
• W3043497346 hasConcept C2776874634 @default.
• W3043497346 hasConcept C2776912625 @default.
• W3043497346 hasConcept C2779134260 @default.
• W3043497346 hasConcept C2780011451 @default.
• W3043497346 hasConcept C2780022809 @default.
• W3043497346 hasConcept C2780868729 @default.
• W3043497346 hasConcept C50440223 @default.
• W3043497346 hasConcept C71924100 @default.
• W3043497346 hasConcept C72563966 @default.
• W3043497346 hasConcept C90924648 @default.
• W3043497346 hasConceptScore W3043497346C126322002 @default.
• W3043497346 hasConceptScore W3043497346C141071460 @default.
• W3043497346 hasConceptScore W3043497346C188816634 @default.
• W3043497346 hasConceptScore W3043497346C2776874634 @default.
• W3043497346 hasConceptScore W3043497346C2776912625 @default.
• W3043497346 hasConceptScore W3043497346C2779134260 @default.
• W3043497346 hasConceptScore W3043497346C2780011451 @default.
• W3043497346 hasConceptScore W3043497346C2780022809 @default.
• W3043497346 hasConceptScore W3043497346C2780868729 @default.
• W3043497346 hasConceptScore W3043497346C50440223 @default.
• W3043497346 hasConceptScore W3043497346C71924100 @default.
• W3043497346 hasConceptScore W3043497346C72563966 @default.
• W3043497346 hasConceptScore W3043497346C90924648 @default.
• W3043497346 hasIssue "Suppl 1" @default.
• W3043497346 hasLocation W30434973461 @default.
• W3043497346 hasOpenAccess W3043497346 @default.
• W3043497346 hasPrimaryLocation W30434973461 @default.
• W3043497346 hasRelatedWork W191524293 @default.
• W3043497346 hasRelatedWork W2010347505 @default.
• W3043497346 hasRelatedWork W2136901070 @default.
• W3043497346 hasRelatedWork W2281102156 @default.
• W3043497346 hasRelatedWork W2340636835 @default.
• W3043497346 hasRelatedWork W2415342018 @default.
• W3043497346 hasRelatedWork W2416230108 @default.
• W3043497346 hasRelatedWork W2807649910 @default.
• W3043497346 hasRelatedWork W3043497346 @default.
• W3043497346 hasRelatedWork W3130205361 @default.
• W3043497346 hasVolume "79" @default.
• W3043497346 isParatext "false" @default.
• W3043497346 isRetracted "false" @default.
• W3043497346 magId "3043497346" @default.
• W3043497346 workType "article" @default.